In The Spotlight
DDNews Cancer Research Exclusive
Recent work with nanoparticles offers a new approach to photo-thermal cancer therapies
(Photo credit: University of Toronto)
The PEARLs (Photothermal Enhancing Auto-Regulated Liposomes) were developed by Dr. Gang Zheng of the Princess Margaret Cancer Centre and University of Toronto and colleagues, who say they overcome traditional roadblocks to penetrate deeper into tumors.
August opened with the news that Epizyme Inc. and US Oncology Research had kicked off a collaboration for the screening and identification of relapsed or refractory follicular lymphoma and diffuse large B-cell lymphoma patients with EZH2 mutations
Adaptive Biotechnologies has launched a translational collaboration with the Cancer Therapy Evaluation Program of the National Cancer Institute
Seattle Genetics exercises option; costs to be split equally with Genmab going forward
ThromboGenics NV has announced, along with BioInvent International AB, that the companies have amended their existing agreement for the co-development of novel anti-P1GF monoclonal antibody products TB-403 and THR-317
Biodesix’s GeneStrat and VeriStrat tests for non-small cell lung cancer pass with flying colors
Independent published data was published this quarter validating Avant Diagnostics Inc.’s proprietary Theralink mTOR phosphoprotein assay in delineating the estrogen receptor positive (ER+) breast cancer (BC) population by mTOR activation status
Diffusion Pharmaceuticals Inc. recently announced the selection of an unnamed “premier clinical research organization” to conduct a Phase 3 clinical trial of trans sodium crocetinate (TSC), Diffusion’s lead molecule, in patients with inoperable glioblastoma multiforme.
Max Planck Innovation, Daiichi Sankyo and the Lead Discovery Center to pursue cancer lead discovery
(Photo credit: NCI, NIH)
The latest Annual Report to the Nation shares that cancer survival rates are rising, while incidence and death rates are on a downward trend
by JK Bryan & A Zupnick, Novella
When it comes to oncology clinical trials, drug developers need to stay abreast of the rapidly evolving and competitive landscape while also remaining flexible and innovative in responding to these changes

by Dr. Alexey Eliseev, RXi
The “War on Cancer” declared by the National Cancer Act of 1971 proceeded through a series of evolutionary developments in chemotherapy, radiation treatments and targeted therapies, but until recently was only marginally successful in extending the lives of late-stage cancer patients. A major breakthrough has been achieved over the last decade with the development of immunotherapeutic treatments that empower a patient’s own immune cells to destroy tumors

by Dr. Brad Thompson, Oncolytics
During these heady and still-early days in the age of clinical studies involving immunotherapy, it is useful to ponder some of the outstanding questions these studies raise

Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.